Targeting Src in breast cancer.
暂无分享,去创建一个
[1] D. Mukhopadhyay,et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.
[2] R. Jove,et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. , 2006, Cancer research.
[3] Hua Yu,et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.
[4] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[5] R. Tootell,et al. Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor , 2005 .
[6] R. Roskoski,et al. Src kinase regulation by phosphorylation and dephosphorylation. , 2005, Biochemical and biophysical research communications.
[7] W. Gradishar,et al. Gene expression in breast cancer , 2006, Current treatment options in oncology.
[8] S. Parsons,et al. Characterization of human epidermal growth factor receptor and c‐Src interactions in human breast tumor cells , 1998, Molecular carcinogenesis.
[9] D. Bowtell,et al. Cbl Associates with Pyk2 and Src to Regulate Src Kinase Activity, αvβ3 Integrin-Mediated Signaling, Cell Adhesion, and Osteoclast Motility , 2001, The Journal of cell biology.
[10] Silvia Bernardini,et al. Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation , 2000, The Journal of cell biology.
[11] J. M. García-Martínez,et al. Role of c-Src in Human MCF7 Breast Cancer Cell Tumorigenesis* , 2006, Journal of Biological Chemistry.
[12] Alan Cantor,et al. Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression , 2006, Clinical Cancer Research.
[13] Paul J. Williams,et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. , 2003, Cancer research.
[14] P. Ji,et al. Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Gallick,et al. Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.
[16] C. Cordon-Cardo,et al. A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.
[17] D. Yu,et al. Upregulation and activation of PKCα by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCα and Src inhibitors , 2006, Oncogene.
[18] J. Dering,et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.
[19] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[20] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[21] Moshe Talpaz,et al. Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.
[22] T. Miyake,et al. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function , 2007, Oncogene.
[23] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[24] M. Zimmer,et al. EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. , 2002, Molecular cell.
[25] Paul Workman,et al. Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis* , 2004, Journal of Biological Chemistry.
[26] V. Jordan,et al. Steroid receptors and their role in the biology and control of breast cancer growth. , 2006, Seminars in oncology.
[27] Fei Huang,et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.
[28] D. Mukhopadhyay,et al. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. , 2001, Cancer research.
[29] D. Edwards,et al. Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones. , 2004, Essays in biochemistry.
[30] I. Macdonald,et al. Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.
[31] M. Maa,et al. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Fuqua,et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor–positive human breast cancer cells , 2006, Molecular Cancer Therapeutics.
[33] Fei Ye,et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. , 2005, Cancer research.
[34] Sheila M. Thomas,et al. Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.
[35] Allan Bradley,et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.
[36] D. Drucker,et al. Parathyroid hormone-related peptide is a downstream target for ras and src activation. , 1994, The Journal of biological chemistry.
[37] C. Vogel,et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. , 2005, Clinical breast cancer.
[38] W. Muller,et al. c-Src-null mice exhibit defects in normal mammary gland development and ERα signaling , 2005, Oncogene.
[39] Timothy J. Yeatman,et al. A renaissance for SRC , 2004, Nature Reviews Cancer.
[40] L. Luttrell,et al. Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src , 1988, Molecular and cellular biology.
[41] D. Fujita,et al. Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells , 2002, BMC Biochemistry.
[42] P. Altevogt,et al. Role of Src Kinases in the ADAM-mediated Release of L1 Adhesion Molecule from Human Tumor Cells* , 2000, The Journal of Biological Chemistry.
[43] Wolfgang Heller,et al. Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.
[44] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[45] R. Eastell,et al. The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males , 2005 .
[46] S. Rabbani,et al. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. , 2007, Cancer research.
[47] D. Holt,et al. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. , 2000, Chemistry & biology.
[48] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[49] Yi Zhang,et al. Genes associated with breast cancer metastatic to bone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] F. Lee,et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. , 2006, The American journal of pathology.
[51] R. Nicholson,et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells , 2006, Breast Cancer Research and Treatment.
[52] J. Parsons,et al. pp60c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src , 1989, Molecular and cellular biology.
[53] R. Nicholson,et al. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells , 2007, Clinical & Experimental Metastasis.
[54] E. Avizienyte,et al. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. , 2005, Current opinion in cell biology.
[55] T. Yoneda,et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.
[56] P. Yaciuk,et al. Overexpression of the c-src protein does not induce transformation of NIH 3T3 cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[57] F. Lee,et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo , 2005 .
[58] L. Otterbein,et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.
[59] G. Staal,et al. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.
[60] H. Rugo,et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) , 2005 .
[61] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[62] Monilola A. Olayioye,et al. ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases* , 1999, The Journal of Biological Chemistry.
[63] N. Hynes,et al. An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway. , 2001, Experimental cell research.
[64] M. Shupnik. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation , 2004, Oncogene.
[65] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[66] G. Rijksen,et al. c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS , 1996, The Journal of pathology.
[67] N. Tokudome,et al. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways , 2007, Breast cancer.
[68] H. Rübsamen,et al. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. , 1983, Cancer research.